Video

Sarah Sciortino on Fertility and Sexuality in Younger Patients with Ovarian Cancer

Author(s):

Sarah Sciortino, MSW, LSW
Conference|Ovarian Cancer National Conference

Sarah Sciortino, MSW, LSW, Oncology Psychosocial Support Services Program Coordinator at University of Chicago Hospital, discusses the unique concerns that younger patients with ovarian cancer can face.

Sarah Sciortino, MSW, LSW, Oncology Psychosocial Support Services Program Coordinator at University of Chicago Hospital, discusses the unique concerns that younger patients with ovarian cancer can face. Decisions about fertility often have to be made quickly, and at a much earlier time than patients are prepared for. Additionally, body image and sexuality can be affected dramatically by treatment.

Related Videos
Image of doctor with brown hair.
Image of Doctor with blonde hair.
Primary urothelial cancer has variable histologies, making its treatment complex, leading to varied outcomes with high rates of recurrence in patients.
Dr. Neeraj Agarwal is a medical oncologist, a professor of medicine and the Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute, University of Utah, as well as director of the Genitourinary Oncology Program and the Center of Investigational Therapeutics at the Huntsman Cancer Institute in Salt Lake City.
Image of Dr. Goy.
Image of bald man.
Dr. Anna Arthur is the Director of the Medical Nutrition Science Program, as well as a tenure-track Assistant Professor in the Department of Dietetics and Nutrition at the University of Kansas Medical Center.
Image of Dr. Scott Kopetz
Image of Dr. Susumu Hijoka
Kate, Princess of Wales, ‘Got So Attached’ to Her Port During Cancer Treatment
Related Content
Illustration of bladder.
February 21st 2025

Neoadjuvant Chemotherapy Plus Chemoradiation Safe, Effective in Bladder Cancer

Roman Fabbricatore
For some patients with bladder cancer, neoadjuvant chemotherapy plus bladder-saving concurrent chemoradiation therapy was effective in the long term.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
Illustration of bladder cancer.
February 20th 2025

Bavencio and BSC Extends Survival in Bladder Cancer, Regardless of Diabetes Status

Jax DiEugenio
Patients with advanced urothelial carcinoma had prolonged survival with Bavencio and BSC treatment, regardless of diabetes mellitus status.
cancer horizons image for podcast
December 14th 2023

Conference Highlights from the 2023 ASH Annual Meeting

Brielle Benyon Alex Biese
CURE® recently covered the 2023 American Society of Hematology Annual Meeting. In case you missed it, here is some news that came out of the conference that patients should know about.
In patients with low-grade, intermediate-risk NMIBC, UGN-102 generated robust, durable responses. © stock.adobe.com.
February 18th 2025

UGN-102 Shows Complete Response Rates in Low-Grade Bladder Cancer

Ashling Wahner
Among patients with low-grade, intermediate-risk NMIBC, UGN-102 generated robust, durable responses in an analysis of the phase 3 ENVISION and ATLAS studies.
Illustration of bladder.
February 18th 2025

Padcev Plus Keytruda Results in Survival, Progression Benefits in Urothelial Carcinoma

Kristi Rosa
Padcev plus Keytruda was found to maintain benefit over chemotherapy in untreated locally advanced or metastatic urothelial cancer.